Navigation Links
Photos: Lumixyl(TM) Enters the Market to Improve the Appearance of Hyperpigmentation without Irritation and Side Effects

NEW YORK, Aug. 6 /PRNewswire/ -- Lumixyl(TM) a non-toxic, non-irritating, synthetic peptide technology shown to significantly help improve the appearance of unwanted discoloration, age spots, sun spots and uneven skin tone is now available through select physicians to help their patients achieve picture perfect skin. A hydroquinone alternative, this new cosmeceutical skin brightening cream can be found in leading physician offices for $120 per 1 ounce pump.

To view the Multimedia News Release, go to:

(Photo: )

Developed by dermatological researchers at Stanford University, Lumixyl's ground-breaking technology is the only peptide shown to measurably promote healthy skin function in restraining tyrosinase, the enzyme responsible for initiating the overproduction of melanin, that can cause uneven pigmentation and dark spots.

Lumixyl is created for patients seeking more even skin-tone including those with:

  • Melasma
  • Post-inflammatory hyperpigmentation
  • Sun spots, age spots or liver spots
  • Photodamage
  • Hyperpigmentation caused by systemic disease or prescription drugs

Clinical studies demonstrate that topical use of Lumixyl visibly improves mild to moderate hyperpigmentation with excellent volunteer satisfaction in as little as 8 weeks. Studies show that Lumixyl, a chain of ten amino acids, promoted the moderation of melanin more efficaciously than hydroquinone. At equal concentrations, skin that was treated with the Lumixyl peptide expressed a reduced production of melanin by as much as 40 percent compared to those treated with hydroquinone, which reduced production by only 7 percent in the study.

"The results of studies conducted at Stanford are impressive, showing a 40 percent improvement in melanin related darkening.," commented Nowell Solish, MD, FRCP, Assistant Professor at The University of Toronto, co-director of the Non-Melanoma Skin Cancer clinic at Women's College. "When used as directed, Lumixyl appears to significantly help the skin's ability to diminish dark spots imparting users with brighter, more even skin tone while limiting irritation, red blotches or even sensitivity to sunlight."

Moreover, in-use and Repeated Insult Patch Testing (RIPT) studies confirm that Lumixyl is safe for topical use and does not elicit irritation or allergic reaction. It does not cause increased sensitivity to sunlight as do many commonly used brightening agents and is gentle for all skin types and tones.

"Hydroquinone has had some controversy in the recent past and this product offers a non-hydroquinone alternative that shows good clinical efficacy in treating discoloration without causing irritation," stated Neil Sadick, MD, FAAD, FAACS, FACP, FACPh.

Lumixyl Topical Brightening Creme can be used alone or if directed by a physician, to compliment other treatments such as Tretinoin, laser resurfacing and SilkPeel(TM), respectively, to diminish dark spots, uneven pigmentation and improve overall skin tone.

Visible Results without Risk

The RIPT results show that, unlike many alternative lightening ingredients, this peptide does not cause irritation or allergic reactions. Lumixyl is formulated to provide the following key advantages:

  • Non-toxic
  • Non-irritating
  • Water-soluble
  • Safe for all skin types
  • Produces no harmful by-products
  • Has no cytotoxic effect

Lumixyl products are made exclusively for dermatologists, plastic surgeons and skin oriented aesthetic physicians. The products are co-marketed in the United States by Basis Medical Technologies and Envy Medical.

ABOUT BASIS -- BASIS Medical Technologies specializes in the development and distribution of groundbreaking technologies in medicine and medical aesthetics. Headquartered in Toronto, Canada, BASIS is an innovative technology platform with sales, marketing and training capabilities around the world. With an experienced management team and medical advisory panel, BASIS is committed to delivering and developing cutting-edge medical products internationally. Basis is an exclusive market representative for Lumixyl, a product licensed by Envy Medical Inc..

ABOUT ENVY MEDICAL -- Envy Medical, working through its commercial subsidiary, E Med Inc., develops, markets and sells highly effective non-invasive skin rejuvenation therapies for patients suffering from either dermatologic or aesthetic conditions. The Company's lead products include SilkPeel(R), a breakthrough device combining exfoliation with dermalinfusion(R) for deeper tissue delivery of active ingredients and better patient outcomes. Envy is also the exclusive licensor of skin brightening peptides including Lumixyl, developed at Stanford University. The Lumixyl peptide is now also available as a topical solution for SilkPeel procedures, addressing hyperpigmentation and photo-damage. More information can be found at

For more information on Lumixyl or to locate a dispensing physician near you, please contact:

SOURCE BASIS Medical Technologies
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Photos: New Survey Shows Many Successful Quit Smoking Attempts Made Without Advance Planning
2. Photos: Americas Chronically Ill Children Have New Hope with Hot Gift
3. Photos: Drink Wine and Live Longer - 1907 Madiran and Plaimont Wines of Southwest France Sponsor the Launch of The Red Wine Diet
4. Photos: Niavin Corporation Offers Pain Sufferers a New Way to Address Pain
5. Photos: Compact Barbell System With Flat, Streamlined Profile Travels Easily and Stores Conveniently
6. Photos: New Smoking Prevention Program Launched in Schools
7. Photos: New Kind of Health Care Reform Brings Five-Star Hospitality to Hospital Care
8. Photos: Los Angeles Non Profit Teams With US Troops Stationed in Baghdad and Buaytha in Bringing a 5-Year-Old Blind Iraqi Girl, Whose Father Stands Beside US Combat Team Against Al Qaeda, to the US for a Groundbreaking Artificial Corneal Transplant Surger
9. Photos: The Multiple Sclerosis Association of America Produces a Web Video on the Importance of MRIs
10. Photos: For the First Time Researchers Show Reversal of an Aging Marker in the Human Retina Correlated with Visual Improvement Using a Nutraceutical Matrix (Longevinex(R))
11. Photos: MIKE AND IKE(R) Lemonade Blends(TM) and Alexs Lemonade Stand Foundation Join facebook(R)
Post Your Comments:
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is excited ... To Recovery® program to drive cancer patients to and from their cancer treatments. ... highest quality of life and ongoing independence. Getting to and from medical treatments ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Living, is proud to recognize Dr. Barry M. Weintraub as a prominent plastic ... most beautiful women in the world, and the most handsome men, look naturally ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
(Date:6/24/2016)... Dublin - ... " Global Markets for Spectroscopy Equipment" report ... This report focuses on the global market of ... applications in various applications. The report deals with spectroscopy ... industries: pharmaceutical and biotechnology, food and beverage, and environmental ...
Breaking Medicine Technology: